Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus
To confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in subjects with type 2 diabetes mellitus (T2DM) on previous treatment with insulin glargine. This is done by compa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Comparison of the efficacy and safety of two different dose adjustment regimens for insulin degludec/insulin aspart in subjects with type 2 diabetes mellitus previously treated with insulin glargine
To confirm the efficacy of the insulin degludec/insulin aspart (IDegAsp) twice daily (BID) simple titration algorithm in controlling glycaemia with respect to change from baseline in glycosylated haem...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes
To confirm superiority on glycaemic control of liraglutide versus liraglutide placebo after 26 weeks of treatment when added to pre-existing basal insulin analogue treatment (with or without concomita...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Contusions
To evaluate the safety of NovoSeven® in subjects with brain contusions.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Effect of liraglutide for weight management in pubertal adolescent subjects with obesity
To compare the efficacy of liraglutide versus placebo on weight loss in adolescent subjects with obesity after 56 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes
To evaluate the compatibility of faster acting insulin aspart (FIAsp) and insulin aspart with the external continuous subcutaneous insulin (CSII) system over a 6-week treatment period.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Insulina humana preprandial inhalada con AERx® iDMS más metformina frente a rosiglitazona más metformina en diabetes tipo 2: ensayo de 26 semanas, abierto, multicéntrico, aleatorizado, paralelo para investigar la eficacia y la seguridad
To compare the effect of pre-prandial inhaled human insulin administered with AERx® iDMS to rosiglitazone, both in combination with metformin, on glycaemic control (as measured by change in HbA1c from...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin Eficacia y seguridad del cambio de sitagliptina a liraglutida en pacientes con diabetes de tipo 2 que no logran un control adecuado de la glucemia con sitagliptina y metformina
To confirm superiority of switch from sitagliptin 100 mg/day to liraglutide 1.8 mg/day, both + metformin vs. continued sitagliptin 100 mg/day + metformin on glycaemic control after 26 weeks of treatme...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing the safety and efficacy of insulin degludec and insulin glargine, both with insulin aspart as mealtime insulin in subjects with type 1 diabetes
To compare the rates of severe or BG (blood glucose) confirmed symptomatic hypoglycaemia of IDeg once daily (OD) + IAsp to IGlar OD + IAsp, by demonstrating that the upper limit of the 95% confidence ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes
To confirm that treatment with semaglutide does not result in an unacceptable increase in cardiovascular risk as compared to placebo in adults with type 2 diabetes. This is done by demonstrating that ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17
Suivant